CyDex Pharmaceuticals Revenue
Pharmaceutical Manufacturing • 
Lenexa, Kansas, United States • 11-20 Employees
CyDex Pharmaceuticals revenue & valuation
| Annual revenue | $3,000,000 |
| Revenue per employee | $250,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $9,600,000 |
| Total funding | No funding |
Key Contacts at CyDex Pharmaceuticals
Vincent Antle
Sr. Director Of Technical Operations And Quality Assurance
Jessica Beach
Assoc. Director Captisol Customer Support
Vince Antle
Senior Director Of Tech Ops And Qa
Helen H
Owner
Vince Antle
Sr Director Of Technical Operations And Qa
Company overview
| Headquarters | 10513 W 84th Ter, Lenexa, KS 66214, US |
| Phone number | +18775755593 |
| Website | |
| NAICS | 3254 |
| Employees | 11-20 |
| Socials |
CyDex Pharmaceuticals Email Formats
CyDex Pharmaceuticals uses 1 email format. The most common is {first initial}{last name} (e.g., jdoe@cydexpharma.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@cydexpharma.com | 100% |
About CyDex Pharmaceuticals
CyDex Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs specifically designed to address limitations of current therapies in selected established markets. We have developed a portfolio of product candidates utilizing our drug formulation technology using Captisol® cyclodextrins. Captisol® cyclodextrins are a patent protected, specifically modified family of cyclodextrins designed to improve solubility, stability, bioavailability, safety and/or dosing of a number of active pharmaceutical ingredients, or APIs. In order to maximize our internal resources, experience and technology, we are focusing on the development and commercialization of product candidates for use in the acute care hospital setting. For those product candidates that likely will entail more extensive development and commercialization efforts, we partner with established pharmaceutical or specialty pharmaceutical companies. We also outlicense our Captisol® technology to third parties for use in the development of their own products. CyDex was acquired by Ligand Pharmaceuticals, Inc. in January 2011.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
CyDex Pharmaceuticals has 6 employees across 3 departments.
Departments
Number of employees
Funding Data
CyDex Pharmaceuticals has never raised funding before.
United Kingdom
Portugal
GermanyFrequently asked questions
4.8
40,000 users
